Evidence map›Paper›PMID 28170199›Full record

ReviewStem cells translational medicine2017

Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug Targets.

Kenneth R Boheler, Rebekah L Gundry

Open access · goldAbstract readReview
In one paragraph

Review in Stem cells translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. The quest of cell surface markers for stem cell therapy.Cellular and molecular life sciences : CMLS · 2021
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Kenneth R BohelerStem Cell and Regenerative Medicine Consortium, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China.
Rebekah L GundryDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Medical College of Wisconsin · USUniversity of Hong Kong · HK

Funding

Cell Surface Phenotyping Human Primary CellsR01HL134010 · NHLBI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GUNDRY, REBEKAH L. · 2016 to 2020
$1.9M
Cell Surface Proteins in Human CardiomyocytesR01HL126785 · NHLBI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GUNDRY, REBEKAH L. · 2016 to 2019
$1.5M
Surface Proteins in the Differentiation of Stem Cells to CardiomyocytesR00HL094708 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI GUNDRY, REBEKAH L. · 2011 to 2013
$702k
Surface Proteins in the Differentiation of Stem Cells to CardiomyocytesK99HL094708 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI GUNDRY, REBEKAH L. · 2009 to 2010
$195k
NHLBI NIH HHS K99 HL094708NHLBI NIH HHS R00 HL094708NHLBI NIH HHS R01 HL126785NHLBI NIH HHS R01 HL134010
6 · The paper itself

Abstract

Stem cells and their derivatives hold great promise to advance regenerative medicine. Critical to the progression of this field is the identification and utilization of antibody-accessible cell-surface proteins for immunophenotyping and cell sorting-techniques essential for assessment and isolation of defined cell populations with known functional and therapeutic properties. Beyond their utility for cell identification and selection, cell-surface proteins are also major targets for pharmacological intervention. Although comprehensive cell-surface protein maps are highly valuable, they have been difficult to define until recently. In this review, we discuss the application of a contemporary targeted chemoproteomic-based technique for defining the cell-surface proteomes of stem and progenitor cells. In applying this approach to pluripotent stem cells (PSCs), these studies have improved the biological understanding of these cells, led to the enhanced use and development of antibodies suitable for immunophenotyping and sorting, and contributed to the repurposing of existing drugs without the need for high-throughput screening. The utility of this latter approach was first demonstrated with human PSCs (hPSCs) through the identification of small molecules that are selectively toxic to hPSCs and have the potential for eliminating confounding and tumorigenic cells in hPSC-derived progeny destined for research and transplantation. Overall, the cutting-edge technologies reviewed here will accelerate the development of novel cell-surface protein targets for immunophenotyping, new reagents to improve the isolation of therapeutically qualified cells, and pharmacological studies to advance the treatment of intractable diseases amenable to cell-replacement therapies. Stem Cells Translational Medicine 2017;6:131-138.

Indexed as

Molecular Targeted TherapyAnimalsBiomarkersDrug RepositioningHumansImmunophenotypingMembrane GlycoproteinsStem CellsBiomarkersMembrane GlycoproteinsDrug targetImmunophenotypingPluripotent stem cellsProteomicsStem cellTechnology

Identifiers

PMID28170199
PMCPMC5442750
OpenAlexW2491041383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.